Early results show promise for strep vaccine

August 10, 2004

CHICAGO - Preliminary results from a trial for a streptococcal vaccine indicate the vaccine appears likely to offer protection against streptococcal infections, according to a study in the August 11 issue of JAMA, the Journal of the American Medical Association.

Efforts to develop a vaccine to prevent group A streptococcal (a type of bacteria that commonly causes illness) infections have been ongoing for more than 70 years, according to background information in the article. Recent advances have allowed previous obstacles associated with group A streptococcal vaccine development to be overcome. Group A streptococcal infections and their sequelae represent a global health problem.

Karen L. Kotloff, M.D., of the University of Maryland School of Medicine, Baltimore, and colleagues report on a preliminary study evaluating the safety and immune reactivity of a group A streptococcal vaccine in healthy volunteers. The phase 1 vaccine trial included 28 adult volunteers aged 18 to 50 years recruited from the metropolitan area of Baltimore between October 1999 and February 2003. Each volunteer received 3 spaced intramuscular injections of either 50 micrograms (n=8), 100 micrograms (n=10), or 200 micrograms (n=10) of group A streptococcal vaccine formulated with aluminum hydroxide into the deltoid muscle of alternating arms.

"Our findings, albeit in a small number of participants, suggest that in the full dose range tested, the vaccine appears safe and well tolerated and does not evoke antibodies that cross-react with human tissue. We have identified a dose (200 micrograms) and schedule (0, 28, and 112 days) that appears to be capable of inducing immune responses ... that are likely to confer protection against multiple group A streptococcal M types."
(JAMA. 2004;292:709-715. Available post-embargo at JAMA.com)

Editor's Note: This study was supported by a U.S. Public Health Service contract from the National Institutes of Health to Myron M. Levine, M.D., and by grant and research funds from the Department of Veterans Affairs to co-author Dr. Dale. For the financial disclosures of the authors, please see the JAMA article.

Editorial: Challenges Ahead for Group A Streptococcal Vaccines

In an accompanying editorial, Michael E. Pichichero, M.D., of the University of Rochester Medical Center, Rochester, N.Y., writes that the challenges for successful development of group A streptococcal vaccines are substantial.

"Very stringent and early studies will lengthen the development process. Uncertainties about targeted immunologic parameters will complicate analysis. Most likely the proposed safety assessment will continue in adults and eventually will progress in phase 2 studies in children.

Double-blind, placebo-controlled, stepwise evaluations in cohorts of children with declining age ranges should be anticipated. There will be a need to conduct large prelicensure trials involving 10,000 to 60,000 participants to provide assurance that rare adverse events are not associated with vaccination, particularly with M type vaccines that have demonstrated adverse events in the past. Safety concerns regarding cross-reaction with human tissues necessitates caution," Dr. Pichichero concludes. (JAMA. 2004;292:738-739. Available post-embargo at JAMA.com)
For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA (5262) or email: mediarelations@jama-archives.org.

Media Advisory: To contact Karen L. Kotloff, M.D., call Ellen Beth Levitt at 410-328-8919. To contact editorial author
Michael E. Pichichero, M.D., call Travis Anderson at 585-273-1757.

The JAMA Network Journals

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.